{"id":"NCT00152009","sponsor":"Shire","briefTitle":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","officialTitle":"A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-01-29","primaryCompletion":"2003-08-23","completion":"2003-08-23","firstPosted":"2005-09-09","resultsPosted":"2009-11-26","lastUpdate":"2021-06-10"},"enrollment":345,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"interventions":[{"type":"DRUG","name":"SPD503 (Guanfacine hydrochloride) (2 mg)","otherNames":[]},{"type":"DRUG","name":"SPD503 (3 mg)","otherNames":[]},{"type":"DRUG","name":"SPD503 (4 mg)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SPD503 (Guanfacine HCl) (2 mg)","type":"EXPERIMENTAL"},{"label":"SPD503 (3 mg)","type":"EXPERIMENTAL"},{"label":"SPD503 (4 mg)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17","primaryOutcome":{"measure":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at Up to 5 Weeks","timeFrame":"Baseline and up to 5 weeks","effectByArm":[{"arm":"SPD503 2mg","deltaMin":-15.93,"sd":1.37},{"arm":"SPD503 3mg","deltaMin":-16.03,"sd":1.38},{"arm":"SPD503 4mg","deltaMin":-18.51,"sd":1.39},{"arm":"Placebo","deltaMin":-8.51,"sd":1.42}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0006"},{"comp":"OG001 vs OG003","p":"0.0005"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18166547"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html","http://www.intuniv.com/documents/INTUNIV_Full_Prescribing_Information.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Headache","Somnolence","Fatigue","Abdominal pain upper","Sedation"]}}